Avidity Biosciences

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , Feb. 28, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2022 and highlighted recent corporate progress. "In 2022, we executed on our goal of advancing three rare disease programs into clinical development and demonstrated the first-ever successful targeted delivery of RNA into muscle, a revolutionary advancement for the field of RNA therapeutics," said Sarah Boyce, president and chief executive officer at Avidity.

Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights

W. Michael Flanagan, Ph.D. named chief scientific and technical officer SAN DIEGO , Feb. 23, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Arthur A.

Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader

Alset EHome International

CymaBay Therapeutics

Fate Therapeutics

Hall of Fame Resort & Entertainment

Century Therapeutics

P3 Health Partners Inc

Summit Therapeutics

Trean Insurance Group

Viking Therapeutics

Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.

5 Best and Worst Performing Small-Cap Stocks in Dec 2022

Avidity Biosciences possesses the only RNA agent capable of being delivered into the muscle. The company's platform success opens up its pipeline to rare muscle diseases and previously unreachable tissue targets such as cardiac muscle.

Avidity Biosciences Will Rise As It Revolutionizes The Field Of RNA Therapeutics

Avidity Biosciences' stock was up 55% last week after releasing preliminary data from a Phase 1/ 2 study of its antibody-oligonucleotide technology candidate in treating myotonic dystrophy type 1. The next price-moving catalyst is the updated Phase 1/2 MARINA trial data in 2023 (likely in mid-2023).

Avidity Biosciences: Unique Antibody-Oligonucleotide Conjugate Technology

SAN DIEGO , Dec. 15, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $17.25 per share. All of the shares to be sold in the offering are to be sold by Avidity.

Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Kymera Therapeutics

Business wins are shining the spotlight on these two companies.

These Biotech Stocks Are the Nasdaq's Big Wednesday Winners

Avidity unveiled "compelling" results from a muscular dystrophy study Wednesday, leading RNA stock to skyrocket to a three-month high. The post How A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The Stratosphere appeared first on Investor's Business Daily.

How A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The Stratosphere

Avidity Biosciences Inc   (NASDAQ:RNA) is soaring this morning, after the biotech company shared positive data from a trial demonstrating the first-ever successful targeted delivery of RNA into muscle.

RNA Breakthrough Sends Biotech Stock Surging

Shares of Avidity Biosciences Inc. RNA, -4.52% soared 39% in premarket trading on Wednesday after the company said its experimental RNA therapy, when injected into the muscle, has potential as a treatment for myotonic dystrophy type 1, a sometimes fatal neuromuscular disease. The Phase 1/2 clinical trial is the first time that RNA has been delivered into the muscle in humans, Avidity said.

Avidity's stock rallies 39% on new RNA data

The heavy selling pressure might have exhausted for Avidity Biosciences, Inc. (RNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 15.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Avidity Biosciences, Inc. (RNA)

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 15.46% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates

Company has three distinct rare disease programs in clinical development - myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD) On track for preliminary assessment of AOC 1001 MARINA™ trial in fourth quarter SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress.        "Consistent with our guidance for 2022, we have progressed three programs addressing three distinct rare diseases into clinical development, and we remain on track for our preliminary assessment of the MARINA™ trial this quarter," said Sarah Boyce, president and chief executive officer.

Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights

New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Avidity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avidity Biosciences, Inc. - RNA

SAN DIEGO , Oct. 6, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the company will be presenting five poster presentations including the MARINA™ study design for myotonic dystrophy type 1 and preclinical and real-world data from the facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD) programs. The posters will be presented at the 27th International Hybrid Annual Congress of the World Muscle Society (WMS), taking place October 11-15, 2022 in Halifax, Nova Scotia, Canada.

Avidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle Society

Atlanta, Georgia--(Newsfile Corp. - September 29, 2022) - Holzer & Holzer, LLC is investigating whether Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA) complied with federal securities laws. On September 27, 2022, Avidity announced that the U.S. Food and Drug Administration has placed a partial clinical hold on new participant enrollment in its Phase 1/2 MARINA clinical trial following a serious adverse event. After this announcement, the Company's stock price dropped.

SHAREHOLDER ALERT: Investigation of Avidity (RNA) Announced by Holzer & Holzer, LLC

Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.

Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study

The FDA placed a myotonic dystrophy study from Avidity Biosciences on partial hold Tuesday, leading RNA stock to collapse. The post Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study appeared first on Investor's Business Daily.

Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study

Shares of Avidity Biosciences Inc. RNA, +1.13% tumbled 23.7% in premarket trading on Tuesday after the company said the Food and Drug Administration placed a partial clinical hold on new enrollment in a Phase 1/2 clinical trial trial evaluating a new treatment for myotonic dystrophy type 1, a progressive neuromuscular disease. Avidity said the partial hold is the result of a serious adverse event reported in one patient.

Avidity shares fall 23% after announcing partial clinical hold for myotonic dystrophy trial

Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs now advancing into the clinic Company to host investor webcast today at 8:30 a.m. ET / 5:30 a.m.

Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

FibroGen

Heron Therapeutics

ImmunityBio

Nkarta, Inc.

Relay Therapeutics, Inc.

Sana Biotechnology

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

7 Unknown Biotech Stocks That Could Rocket in 2023

Company remains on track to have three muscular dystrophy programs in clinic by end of year  SAN DIEGO, Sept. 7, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), honors National Muscular Dystrophy Awareness Month, an annual observance that raises awareness for families across the nation who are living with neuromuscular diseases.

Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -24.32% and 4.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Lags Revenue Estimates

Company remains on track to have three programs in the clinic by the end of this year Programs are for three distinct rare diseases - myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD) SAN DIEGO , Aug. 9, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the second quarter ended June 30, 2022 and highlighted recent corporate progress.        "We are very pleased with the team's execution on our ambitious goal of having three AOC programs addressing three distinct rare diseases in the clinic by the end of this year," said Sarah Boyce, president and chief executive officer.

Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Adults with myotonic dystrophy type 1 (DM1) in the AOC 1001 Phase 1/2 MARINA™ clinical trial can receive continuity of care as part of MARINA-OLE™ Preliminary assessment of safety, tolerability and key biomarkers from Phase 1/2 MARINA trial on track for Q4 2022 SAN DIEGO , Aug. 2, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has commenced enrolling patients from the Phase 1/2 MARINA™ study into a Phase 2 open-label extension study (MARINA-OLE™) of AOC 1001 in adults with myotonic dystrophy type 1 (DM1). All patients enrolled in the randomized, placebo-controlled MARINA™ clinical trial with AOC 1001 are eligible to enroll in MARINA-OLE.

Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study

News for Avidity Biosciences Stock (RNA)